Alessandro Santin
Co-Chief, Section of Gynecologic Oncology · Yale School of Medicine
Credentials: · · · ·
History
PresentSection of Gynecologic Oncology · Yale School of Medicine
- 2008–Present
- 1994–1995
University of California
- 1989–1994
Research
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer
New England Journal of Medicine · 2022 · 797 citations
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
New England Journal of Medicine · 2019 · 702 citations
Annals of Oncology · 2019 · 695 citations
- PS
108 papers
104 papers · 28 as a fellow
95 papers
78 papers · 12 as a fellow
70 papers · 15 as a fellow
59 papers
58 papers
50 papers · 46 as a resident
Grants
- 2014–2019
Integrated Genomic Analysis of Racial Disparities in Endometrial Cancer
National Cancer Institute · U01
Contact PI · $1.7M · Yale University
- 2011–2016
CPE Peptide-Based Nanoparticles for the Diagnosis and Therapy of Chemotherapy Res
National Cancer Institute · R01
Contact PI · $1.7M · Yale University
- 2008–2012
Treatment of Chemotherapy-Resistant Human Ovarian Cancer by Administration of CPE
National Cancer Institute · R01
Contact PI · $1.4M · Yale University
- 2003–2006
Dendritic Cell Immunotherapy for Cervical Cancer
National Cancer Institute · R21
Contact PI · $469.6K · Univ of Arkansas for Med Scis
Clinical trials
- 2024–2027
A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients
Principal investigator · Active not recruiting · Phase 2
Yale University
- 2023–2028
A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer
Principal investigator · Recruiting · Phase 2
Yale University
- 2020–2028
Principal investigator · Recruiting · Phase 2
Alessandro Santin
- 2020–2027
A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma
Principal investigator · Active not recruiting · Phase 2
Yale University